Endocrinology News

Excessive abdominal fat was tied to chronic pain across multiple sites, particularly in women, an analysis published in Regional Anesthesia & Pain Medicine showed.

Use of glucagon-like peptide-1 receptor agonists was associated with a reduced risk for progression to cirrhosis and other complications in patients with metabolic dysfunction-associated steatotic liver disease and diabetes, data showed.

The 2024 election is one of the most consequential elections in recent history, and as physicians, we have a responsibility to vote.

Adults with type 2 diabetes using metformin before or during a SARS-CoV-2 infection may have a lower risk for long COVID than those using other diabetes medications, according to findings published in Diabetes Care.

In patients with basal insulin-treated type 2 diabetes, sotagliflozin was associated with greater time in range compared with placebo at 18 weeks, researchers reported at the European Association for the Study of Diabetes Annual Meeting.

Most physicians and residents report feelings of burnout, while stigma about receiving mental health care remains prevalent, according to a new report from The Physicians Foundation.

Use of AI in medicine is growing quickly. Clinicians are eager to learn what the technology can do, and speakers at meetings across specialties are envisioning its effects — good and bad — in practice management and patient care.

An oral medication to treat children with achondroplasia has received breakthrough therapy designation from the FDA, BridgeBio Pharma announced.

In a first-in-human study, a novel oral amylin and GLP-1 receptor coagonist was safe and tolerable and lowered weight compared with placebo at 12 weeks in patients with obesity, researchers reported.

The FDA has cleared a continuous glucose monitoring system with an implantable sensor that can be worn for up to 1 year for adults aged 18 years and older with type 1 or type 2 diabetes, according to a press release.